Data Sheet (Cat.No.T14127)

TargetMol

Adenosine A1 receptor activator T62

Chemical Properties



CAS No. : 40312-34-3

Formula: C15H14ClNOS

Molecular Weight: 291.8

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Adenosine A1 receptor activator T62 is an allosteric enhancer of the adenosine A1 receptor, producing antinociception in animal models of acute pain and reducing hypersensitivity in models of inflammatory and nerve-injury pain[1][2][3].
Targets(IC50)	Adenosine Receptor
In vivo	Intrathecal administration of the adenosine A1 receptor activator T62 (0.3-3 μg) in male Sprague-Dawley rats produces a dose-dependent antihypersensitivity effect without affecting ambulation or activity levels[1].
Animal Research	Intrathecal T62 of Male SpragueDawley rats (250 g) after paw incision surgery with the dose of 0.3 μg, 0.5 μg, 1 μg, and 3 μg, produced a dose-dependent antihypersensitivity effect, with no effect on ambulation or activity level. The ED40 (95% confidence interval) for T62 was 0.77 (0.63-0.91) microg.

Solubility Information

Solubility	DMSO: 75 mg/mL (257.03 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.427 mL	17.135 mL	34.270 mL
5 mM	0.6854 mL	3.427 mL	6.854 mL
10 mM	0.3427 mL	1.7135 mL	3.427 mL
50 mM	0.0685 mL	0.3427 mL	0.6854 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Obata H, et al. Spinal adenosine receptor activation reduces hypersensitivity after surgery by a different mechanism than after nerve injury. Anesthesiology. 2004 May;100(5):1258-62.
Li X, et al. Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism. J Pharmacol Exp Ther. 2003 Jun;305(3):950-5.
Soudijn W, et al. Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discov Today. 2004 Sep 1;9(17):752-8.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481